sponsored
PatientsVille.com Logo

PatientsVille

Duract Medical Research Studies

Up-to-date List of Duract Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Duract Medical Research Studies

Rank Status Study
1 Recruiting Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery
Conditions: Cataract;   Retinal Edema;   Inflammation
Interventions: Drug: Prolensa (bromfenac 0.07%);   Drug: Ilevro (nepafenac 0.3%)
Outcome Measures: Treatment of inflammation associated with cataract surgery;   Visual Acuity
2 Not yet recruiting A Dose-Finding Study Comparing InSite Vision, Inc. 101 to Vehicle and DuraSite Alone for Dry Eye Disease
Condition: Dry Eye Disease
Intervention: Drug: ISV 101
Outcome Measure: Number of Participants with Adverse Events
3 Unknown  Bromday Versus Nevanac Eye Drops to Control Pain Following Photorefractive Keratectomy
Condition: Myopia
Intervention: Drug: Bromfenac
Outcome Measures: Post-PRK pain;   Post-PRK epithelial healing
4 Recruiting Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery
Conditions: Cataract;   Pseudoexfoliation Syndrome
Interventions: Drug: Dexamethasone+Tobramycin eye drop;   Drug: Bromfenac eye drop
Outcome Measures: Change from baseline in anterior chamber inflammation measured by Laser Flare Photometry (photon counts per millisecond);   Proportion of patients with central macular thickness greater than 300 microns;   Proportion of subjects with best corrected visual acuity equal to 20/20;   Proportion of patients who had no ocular pain
5 Unknown  Safety Study of Bromfenac Ophthalmic Solution in Subjects With Diffuse Diabetic Macular Edema (DME) Refractory to Laser
Condition: Diabetic Macular Edema
Intervention: Drug: Bromfenac ophthalmic solution
Outcome Measures: The mean change in visual acuity and central retinal thickness from baseline to month 3,and the incidence and severity of ocular adverse events and other adverse events.;   Changes in retinal leakage as determined by fluorescein angiography
6 Recruiting PRevention of Macular EDema After Cataract Surgery
Conditions: Cystoid Macular Edema;   Cataract;   Diabetes Mellitus
Interventions: Drug: Bromfenac;   Drug: Dexamethasone;   Drug: Bevacizumab;   Drug: Triamcinolone Acetonide
Outcome Measures: Change in central subfield mean macular thickness as a measurement of efficacy;   No. of subjects developing clinically significant macular edema as a measurement of efficacy
7 Unknown  Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following Phacoemulsification
Conditions: Pseudophakia;   Cataract Surgery
Interventions: Drug: Pred Forte;   Drug: Lotemax
Outcome Measure: Prevention Of Retinal Thickening
8 Recruiting Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas
Conditions: Keratoconus;   Ectasia;   Degeneration
Interventions: Drug: Ciprofloxicine or Vigamox or other.;   Drug: Nonsteroidal (Acular, Voltaren Xibrom, etc);   Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Outcome Measures: Increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within;   increase the biomechanical and biochemical stability of the cornea between collagen fibers using UVA light and the photo- mediator riboflavin
9 Recruiting Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas
Conditions: Keratoconus;   Ectasia;   Degeneration
Interventions: Drug: Ciprofloxicin or Vigamox or other.;   Drug: Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc);   Drug: Steroid (FML, Pred Forte, Flarex, etc.)
Outcome Measures: Increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within;   increase the biomechanical and biochemical stability of the cornea between collagen fibers using UVA light and the photo- mediator riboflavin
10 Not yet recruiting Comparative Study to Evaluate ISV-305 Compared to Vehicle in Non-Bacterial Blepharitis Subjects
Condition: Non-Bacterial Blepharitis
Interventions: Drug: ISV-305;   Other: Vehicle
Outcome Measure: Clinical Resolution
11 Recruiting Study to Determine the Effect of Azasite on Corneal Surface Irregularity
Condition: Meibomian Gland Dysfunction
Intervention: Drug: Azasite
Outcome Measures: Change in Corneal Irregularity Measurement;   Global symptoms score;   Meibomian gland secretion characteristics;   Best corrected distance visual acuity;   Corneal staining;   Axial topography based astigmatism pattern;   Intraocular Lens(IOL) Master Keratometry
12 Recruiting Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas (2)
Conditions: Keratoconus;   Ectasia;   Degeneration
Intervention:
Outcome Measures: Increase the biomechanical and biochemical stability of the cornea by inducing additional cross-links within;   increase the biomechanical and biochemical stability of the cornea between collagen fibers using UVA light and the photo- mediator riboflavin

These studies may lead to new treatments and are adding insight into Duract etiology and treatment.

A major focus of Duract research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Duract